Pay with

USD

Supports Visa, Mastercard, SEPA & more

Flexible trading, zero fees

Use your crypto for payments worldwide

Basic

Trade crypto freely

Smart access to new on-chain tokens

Magnify your profit with leverage

Convert & Auto-Invest

Trade any size with no fees and no slippage

Get exposure to leveraged positions simply

Pre-Market Trading

Trade new tokens before listing

Advanced

Trade on-chain with Gate Wallet

Smart strategies with automated trading

Follow expert trading strategies

CrossEx Trading

One margin balance, shared across platforms

OTC Bank Transfer

Deposit and withdraw fiat

OTC trades with simple RFQ

Access hundreds of perpetual contracts

One platform for global traditional assets

Event Contracts

Predict price moves and seize opportunities

Trade European-style vanilla options

Unified Account

Maximize your capital efficiency

Introduction to Futures Trading

Learn the basics of futures trading

Join events to earn rewards

Use virtual funds to practice risk-free trading

Stock CFD Derivatives

Access real US stocks and ETFs

Trade quality Hong Kong-listed stocks

Real Korean stocks and top assets

Top Japanese stocks, all in one place

High leverage, 24/7 trading

Stocks Activities

Trade Popular Stocks and Unlock Generous Airdrops

Tokenized Stocks

Backed by real stock assets

Unlock full access to global stock IPOs

GUSD Flexible US Treasury

Earn reliable returns from treasury-backed RWAs

Launch

Collect candies to earn airdrops

Quick staking, earn potential new tokens

Hold GT and get massive airdrops for free

Unlock full access to global stock IPOs

Trade on-chain assets and earn airdrops

Earn futures points and claim airdrop rewards

Investment

Trade & earn at the same time

Earn interest with idle tokens

Stake cryptos to earn in PoS products

Auto-invest on a regular basis

Dual Investment

Profit from market volatility

Earn rewards with flexible staking

Limited-Time 4% APR on USDT

Top-tier quant strategies

Earn reliable returns from treasury-backed RWAs

No lock-up, withdraw anytime

Pledge one crypto to borrow another

One-stop lending hub

Post, share, and explore crypto trends

Live crypto market analysis

Chat with crypto traders

What is happening in crypto

Crypto guides and educational resources

Crypto insights and industry updates

In-depth research and market analysis

More

Promotions

Activity Center

Participate in activities to earn rewards

Invite friends to earn referral rewards

Affiliate Program

Earn exclusive commission rewards

Grow influence and earn airdrops

Real-time platform updates

Huge fee discounts

Asset Management

One‑stop asset management solution

Enterprise digital asset solutions

Developers (API)

Connects to the Gate application ecosystem

Generous API rebate mechanisms

Trade on TradingView

Elevate your trading experience

AI

Your all-in-one conversational AI partner

Use Gate AI directly in your social App

Gate Blue Lobster, ready to go

Gate for AI Agent

AI infrastructure, Gate MCP, Skills, and CLI

Gate Skills Hub

From office tasks to trading, the all-in-one skill hub makes AI even more useful.

Others

Find FAQs and help guides

Grow with the champions

Proof of Reserves

Gate promises 100% proof of reserves

Keep your assets secure

Regulatory Licenses, Registrations, and Approvals

Eli Lilly Tops Q2 Estimates with EPS $8.38, Raises 2026 Revenue Outlook to $85-87B as Mounjaro and Zepbound Surge

2026-08-05 10:52:54

According to its Q2 earnings report released on Wednesday, Eli Lilly reported adjusted earnings per share of $8.38 versus $6.01 expected and revenue of $22.97 billion versus $20.73 billion expected. The pharmaceutical giant raised its full-year 2026 revenue guidance to $85-87 billion from a previous range of $82-85 billion. Mounjaro worldwide revenue rose 91% year-over-year to $9.94 billion for the quarter, with U.S. sales of $4.8 billion surpassing the $4.44 billion analysts expected. Zepbound U.S. revenue reached $4.93 billion, up 44% from the prior year and exceeding the $4.69 billion forecast.

Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.

Related News

CVS Health Beats EPS Estimate $2.58 vs $1.85, Raises 2026 Guidance on Insurance Recovery

AMD Reports Q2 Revenue Up 50%, Net Profit Surges 164% as Data Center Business Doubles

Paramount Skydance Raises Full-Year Profit Guidance, Maintains Confidence on WBD Merger

Vertex Pharmaceuticals Raises 2026 Revenue Guidance to $131B–$132B on Strong Q2 Earnings

Pfizer Beats Q2 Estimates With 77-Cent EPS, Raises Full-Year Revenue Guidance

In-Depth Analysis

CVS Health Beats Q2 Estimates, Raises 2026 Guidance on Aetna Recovery

Lucas Bennett08-05 10:51

Lotte Chilsung Beverage Q2 2026 Earnings Meet Expectations at 55.8B Won

Lucas Bennett08-05 04:59

AMD Reports 50% Revenue Growth as Data Center Sales Double

Lucas Bennett08-04 20:47

Comment

0/400

No comments